Concepedia

Scott Delach

SD

11

Publications

843

Citations

11

H-Index

2000

Active since

Affiliations

UPMC Hillman Cancer Center(Current)

Novartis (Switzerland)

Novartis Institutes for BioMedical Research

Genomics Institute of the Novartis Research Foundation

Scott Delach is an author at UPMC Hillman Cancer Center specializing in medicine, cell biology, and cell signaling.

Top concepts

Publications per year

2000–2023

11

Publications

11

Combinations with Allosteric SHP2 Inhibitor TNO155 to Block Receptor Tyrosine Kinase Signaling

Chen Liu, Hengyu Lu, Hongyun Wang et al. · Clinical Cancer Research · 2020 · 156 citations · Full text

Whole Genome Amplification of DNA from Laser Capture-Microdissected Tissue for High-Throughput Single Nucleotide Polymorphism and Short Tandem Repeat Genotyping

Martha Rook, Scott Delach, Galina Deyneko et al. · American Journal Of Pathology · 2004 · 99 citations · Full text

, , +10

Isolation of Bcl-2 Binding Proteins That Exhibit Homology with BAG-1 and Suppressor of Death Domains Protein

Keiko Antoku, Richard S. Maser, W J Scully et al. · Biochemical and Biophysical Research Communications · 2001 · 93 citations

, , +9

Involvement of cathepsin D in chemotherapy-induced cytochrome <i>c</i> release, caspase activation, and cell death

Lori A. Emert‐Sedlak, Sanjeev Shangary, Asaf Rabinovitz et al. · Molecular Cancer Therapeutics · 2005 · 90 citations

The potent and selective cyclin-dependent kinases 4 and 6 inhibitor ribociclib (LEE011) is a versatile combination partner in preclinical cancer models

Sunkyu Kim, Ralph Tiedt, Alice Loo et al. · Oncotarget · 2018 · 88 citations · Full text

Rows per page

1–5 of 11